BTIG Reiterates Buy Rating for Haemonetics Corporation
BTIG reaffirms its buy rating on Haemonetics with a price target of $84, a 11.82% upside from the current price.
Key Points
- BTIG reiterated its buy rating on Haemonetics Corporation on June 26, 2026, with a price target of $84.
- BTIG's $84 price target implies 11.82% upside from Haemonetics Corporation's ($HAE) current $75.12 share price.
- Shares of NYSE:HAE traded near $77.62 on Friday, with a market cap of approximately $3.53 billion.
- Recent insider activity at Haemonetics includes sales by executives and a purchase by the CFO in May.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 26, 2026, BTIG reiterated its buy rating for Haemonetics Corporation (NYSE:HAE), setting a price target of $84. Analyst Marie Thibault emphasized the firm's positive outlook on the company's performance. Shares of Haemonetics traded near $77.62 on Friday.
BTIG vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Haemonetics Corporation
Several institutional investors made moves in their Haemonetics holdings. BlackRock, Inc. trimmed its position by 200,975 shares, holding about 5,619,979 shares valued at $316.7 million, a 3.5% decrease. Neuberger Berman Group LLC also cut its stake by 304,758 shares, ending with 3,560,918 shares worth approximately $200.6 million, a 7.9% reduction. On the other hand, AQR Capital Management LLC increased its holdings by 193,439 shares to a total of 3,356,543 shares valued at around $185.7 million, marking a 6.1% rise. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, with 2,559,316 and 2,090,389 shares, respectively.
Haemonetics Corporation Stock Down 27.7%
Shares of Haemonetics Corporation traded near $77.62 on Friday. The company has a market cap of approximately $3.53 billion and a P/E ratio of 37.86, with a forward P/E of 13.48. Its beta is 0.54, indicating lower volatility compared to the market. Haemonetics' 52-week range is between $47.32 and $87.32. The stock's 50-day moving average is $64.58, while the 200-day moving average is $64.20. The company's current ratio is 2.95, and its quick ratio stands at 1.64, with a debt-to-equity ratio of 160.08.
$HAE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Haemonetics reported revenue of approximately $1.33 billion, reflecting a growth of 4.8%. The company achieved a net margin of 7.29% and a return on equity of 12.03%. Earnings per share were $2.05. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Haemonetics Corporation
Recent insider transactions at Haemonetics include several sales and a notable purchase. On June 5, 2026, Maryanne Maunsell, VP and Chief Accounting Officer, sold 259 shares at an average price of $71.28. Laurie Miller, SVP of Human Resources, also sold 313 shares on the same day. In May, Chief Financial Officer James Darecca purchased 29,312 shares, while Maryanne Maunsell sold 197 shares, and President & CEO Christopher Simon sold 9,681 shares at an average price of $56.29.
Analysts Set New Price Targets
On June 26, 2026, BTIG reiterated its buy rating for Haemonetics with a price target of $84. Earlier, on June 15, Mizuho maintained its buy rating with an $85 target. B of A Securities upgraded Haemonetics to a buy with an $80 target on May 22. The consensus rating is a buy, with a mean target price of $85.20, based on 10 analyst opinions.
About Haemonetics Corporation
Haemonetics Corporation, based in Boston, Massachusetts, is a medical technology company that provides solutions for hospitals and blood centers. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers products like automated plasma collection systems and donor management software. It also provides technologies for critical care and surgery, including the TEG 6s system and the Cell Saver Elite +. Christopher A. Simon is the CEO, and the company employs about 3,009 people.
Bottom Line
BTIG's continued buy rating on Haemonetics reflects confidence in the company's growth potential. Investors often track such analyst ratings for insights into market sentiment. However, it's important to remember that these ratings are based on past performance and projections, which may not reflect future results.
Get Haemonetics Corporation alerts
New 13F filings, insider trades, and analyst moves on $HAE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.